Results 31 to 40 of about 40,457 (265)

Posttransplantation Lymphoproliferative Disease Treated by Retransplantation

Case Reports in Immunology, 2020
Epstein–Barr virus- (EBV-) induced posttransplantation lymphoproliferative disease (PTLD) is a life-threatening complication following allogeneic stem cell transplantation. The main risk factor is anti-thymocyte globulin (ATG).
Ingerid Weum Abrahamsen, Bjørn Christer Grønvold, Else Marit Inderberg, Nadia Mensali, Jonas Mattsson, Tobias Gedde-Dahl   +5 more
doaj   +1 more source

A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest

Cardio-Oncology, 2020
High dose melphalan is commonly used as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. There are reports of adverse cardiac events with melphalan manifested by supraventricular tachycardia and atrial fibrillation ...
Liang-Liang Ma, Ying Liu, Si-Xun Jia, Hai-Chen Lv, Mei-Yun Fang, Yun-Long Xia   +5 more
doaj   +1 more source

Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center

Balkan Medical Journal, 2023
Background: Allogeneic hematopoietic stem cell transplantation is a well-established approach for patients diagnosed with primary myelofibrosis and remains the only potentially curative treatment.
Guldane Cengiz Seval, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin Topcuoglu, Onder Arslan, Taner Demirer, Gunhan Gurman, Meral Beksac, Osman Ilhan, Muhit Ozcan   +10 more
doaj   +1 more source

Comorbid Conditions in Kidney Transplantation [PDF]

Journal of the American Society of Nephrology, 2005
Although the impact of comorbidity on outcomes in ESRD has been evaluated extensively, its contribution after kidney transplantation has not been well studied. It is believed that comorbidity assessment is critical to the informed interpretation of kidney transplant outcomes. In this study, the Charlson Comorbidity Index was used to assess the comorbid
Christine, Wu, Idris, Evans, Raymond, Joseph, Ron, Shapiro, Henkie, Tan, Amit, Basu, Cynthia, Smetanka, Ahktar, Khan, Jerry, McCauley, Mark, Unruh   +9 more
openaire   +2 more sources

Incidence and Severity of Carboplatin‐Associated Hearing Loss in Children With Cancer Assessed by the SIOP Boston 2012 Ototoxicity Criteria

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Platinum‐based chemotherapy is known to cause severe and debilitating hearing loss, but unlike cisplatin, the true incidence of carboplatin‐induced hearing loss remains unclear. We evaluated functional hearing outcomes in children receiving carboplatin to determine the incidence and severity of ototoxicity. Procedure We identified a
Aniket Chawla, Sean Carter, Andrew Wood, Sandra Staffieri, Andrew Dodgshun, David D. Eisenstat, Michael Sullivan   +6 more
wiley   +1 more source

Efficacy of BEAM versus BeEAM conditioning regimens in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: a retrospective single-center study

Frontiers in Oncology
The BEAM regimen (carmustine, etoposide, cytarabine, melphalan) is the standard conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in diffuse large B-cell lymphoma (DLBCL).
Saibiya Akebaer, Gang Chen, Jianli Xu, Kaile Zhang, Ruixue Yang, Chunxia Han, Jia Hou, Ming Jiang, Hailong Yuan   +8 more
doaj   +1 more source

Autologous hematopoietic stem cell transplantation in systemic sclerosis: nursing actions

Revista Eletrônica de Enfermagem, 2014
The objective of this cross-sectional study was to identify the complications and the implemented nursing actions in systemic sclerosis patients undergoing autologous hematopoietic stem cell transplantation, during the conditioning regimen.
Carolina Scoqui Guimarães, Renata Cristina de Campos Pereira Silveira, Loren Nilsen, Maria Carolina de Oliveira Rodrigues   +3 more
doaj   +1 more source

Successful allogeneic bone marrow transplantation using immunosuppressive conditioning regimen for a patient with red blood cell transfusion-dependent pyruvate kinase deficiency anemia

Hematology Reports, 2020
Pyruvate kinase deficiency (PKD) is the rare glycolytic enzyme defect causing hemolytic anemia. Treatments are mainly red cell transfusion and/or splenectomy, leading to iron overload.
Maiko Shimomura, Takehiko Doi, Shiho Nishimura, Yusuke Imanaka, Shuhei Karakawa, Satoshi Okada, Hiroshi Kawaguchi, Masao Kobayashi   +7 more
doaj   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko, Holger N. Lode, Alberto Garaventa, Carla Manzitti, Roberto Luksch, Dominique Valteau‐Couanet, Marion Gambart, John Anderson, Juliet Gray, Adela Canete, Lucas Moreno, Aleksandra Wieczorek, Cormac Owens, Shifra Ash, Isaac Yaniv, Genevieve Laureys, Hans Loibner, Katarzyna Śladowska, Ruth Ladenstein, Paweł Kawalec   +19 more
wiley   +1 more source

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol, Arlene Naranjo, Lulu Chen, Rajen Mody, Steven G. DuBois, Rochelle Bagatell, Navin Pinto   +6 more
wiley   +1 more source